Showing results (31-40 of 133) with videos related to
Sort By:
Pageof 14
Plos One|March 9, 2010
Role of STAT3 in in vitro transformation triggered by TRK oncogenesClaudia Miranda, Tiziana Fumagalli, Maria Chiara Anania, et al.Journal of Experimental & Clinical Cancer Research : CR|September 15, 2017
Liquid dynamic medicine and N-of-1 clinical trials: a change of perspective in oncology researchNicola Silvestris, Gennaro Ciliberto, Paolo De Paoli, et al.The American Journal of Surgical Pathology|March 25, 2008
PDGFRA immunostaining can help in the diagnosis of gastrointestinal stromal tumorsFrancesca Miselli, Clara Millefanti, Elena Conca, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2010
TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squamous cell carcinomaFederica Perrone, Paolo Bossi, Barbara Cortelazzi, et al.Diseases of the Colon and Rectum|November 13, 2004
APC genotype is not a prognostic factor in familial adenomatous polyposis patients with colorectal cancerLucio Bertario, Antonio Russo, Paola Sala, et al.Genes, Chromosomes & Cancer|July 1, 2010
Chromosome band 17q21 in breast cancer: significant association between beclin 1 loss and HER2/NEU amplificationTiziana Negri, Eva Tarantino, Marta Orsenigo, et al.Molecular Endocrinology (Baltimore, Md.)|January 13, 2004
Biological effects of the dual phenotypic Janus mutation of ret cosegregating with both multiple endocrine neoplasia type 2 and Hirschsprung's diseaseElena Arighi, Anna Popsueva, Debora Degl'Innocenti, et al.International Journal of Cancer|May 4, 2006
Regulation of lipocalin-2 gene by the cancer chemopreventive retinoid 4-HPRStefano Caramuta, Loris De Cecco, James F Reid, et al.Cytometry. Part B, Clinical Cytometry|April 5, 2011
High CD133 expression levels in gastrointestinal stromal tumorsFabio Bozzi, Elena Conca, Giacomo Manenti, et al.Proceedings of the National Academy of Sciences of the United States of America|July 19, 2006
MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agentsMartin Monte, Marta Simonatto, Leticia Y Peche, et al.Pageof 14